Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ELEnliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN)

NASDAQ Global Select · Currency in USD
$41.52 ▼ -0.41 (-0.98%)
At close: Oct 23, 4:00 PM ET. Market closed.
$42.00 ▲ +0.48 (+1.16%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$41.93
Open
$41.49
Day's Range
$40.65 – $41.64
52 Week Range
$14.79 – $62.32
Volume
2,298,502
Avg. Volume
1,350,212
Market Cap
$3.04B
Beta (5Y Monthly)
0.25
PE Ratio (TTM)
--
EPS (TTM)
-$1.60
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$76.29

Profile: Enliven Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
67
CEO
Richard A. Fair

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.45
DateEst.Actual
Aug 5, 2026-$0.39-$0.49Miss
May 7, 2026-$0.44-$0.38Beat
Mar 3, 2026-$0.42-$0.48Miss
Nov 12, 2025-$0.43-$0.32Beat
Aug 13, 2025-$0.53-$0.49Beat
May 14, 2025-$0.51-$0.57Miss

Analyst view

Consensus price target
$76.29 ▲ +83.7%
Range $70.00 – $82.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ELVN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.